NATCOPHARM — Natco Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Natco Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	20,945	19,150	20,521	19,448	27,071
Cost of Revenue
Gross Profit	16,805	14,785	15,033	13,445	20,399
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	13,785	14,322	15,628	18,239	19,301
Operating Profit	7,160	4,828	4,893	1,209	7,770
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,247	5,687	5,796	2,022	8,619
Provision for Income Taxes
Net Income After Taxes	6,424	4,581	4,424	1,700	7,153
Minority Interest
Net Income Before Extraordinary Items
Net Income	6,444	4,608	4,409	1,700	7,153
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,444	4,608	4,409	1,700	7,153
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	34.3	24.5	22.8	7.35	38.5
Dividends per Share